SE503482C2 - Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion - Google Patents

Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion

Info

Publication number
SE503482C2
SE503482C2 SE8801406A SE8801406A SE503482C2 SE 503482 C2 SE503482 C2 SE 503482C2 SE 8801406 A SE8801406 A SE 8801406A SE 8801406 A SE8801406 A SE 8801406A SE 503482 C2 SE503482 C2 SE 503482C2
Authority
SE
Sweden
Prior art keywords
compound
hiv
infection
prophylaxis
therapy
Prior art date
Application number
SE8801406A
Other languages
English (en)
Swedish (sv)
Other versions
SE8801406D0 (sv
SE8801406L (sv
Inventor
Patrick Thomas Prendergast
Original Assignee
Colthurst Ltd
Patrick Thomas Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colthurst Ltd, Patrick Thomas Prendergast filed Critical Colthurst Ltd
Publication of SE8801406D0 publication Critical patent/SE8801406D0/xx
Publication of SE8801406L publication Critical patent/SE8801406L/xx
Publication of SE503482C2 publication Critical patent/SE503482C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE8801406A 1987-04-16 1988-04-15 Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion SE503482C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE99787 1987-04-16
IE228987 1987-08-27

Publications (3)

Publication Number Publication Date
SE8801406D0 SE8801406D0 (sv) 1988-04-15
SE8801406L SE8801406L (sv) 1988-10-17
SE503482C2 true SE503482C2 (sv) 1996-06-24

Family

ID=26319024

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8801406A SE503482C2 (sv) 1987-04-16 1988-04-15 Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion

Country Status (23)

Country Link
US (1) US4956355A (fi)
JP (1) JP2577771B2 (fi)
KR (1) KR960014988B1 (fi)
AT (1) AT401470B (fi)
AU (1) AU608824B2 (fi)
BE (1) BE1004315A5 (fi)
CA (1) CA1325594C (fi)
CH (1) CH675358A5 (fi)
DE (1) DE3812595C2 (fi)
DK (1) DK175582B1 (fi)
FI (1) FI881773A (fi)
FR (1) FR2615394B1 (fi)
GB (1) GB2204237B (fi)
GR (1) GR1002240B (fi)
IL (1) IL86089A (fi)
IT (1) IT1227073B (fi)
LU (1) LU87202A1 (fi)
NL (1) NL194728C (fi)
NZ (1) NZ224272A (fi)
OA (1) OA08729A (fi)
PH (1) PH25907A (fi)
PT (1) PT87259B (fi)
SE (1) SE503482C2 (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201819A (ja) * 1985-11-13 1987-09-05 Res Dev Corp Of Japan 免疫不全症処置剤
US5356900A (en) * 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US6638894B1 (en) * 1987-01-09 2003-10-28 Lucent Technologies Inc. Devices and systems based on novel superconducting material
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE3872635T2 (de) * 1987-04-09 1992-12-17 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
EP0494224B1 (en) * 1989-09-25 2000-05-10 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing t cell lymphokine production
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5753237A (en) * 1989-09-25 1998-05-19 University Of Utah Research Foundation Method for augmenting immunological responses
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
IE63418B1 (en) * 1990-09-10 1995-04-19 Elan Corp Plc Progression risk of HIV by assay of dehydroepiandrosterone in body fluid
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
JPH05317041A (ja) * 1991-06-05 1993-12-03 Nippon Oil Co Ltd 動物細胞増殖促進剤及び無血清培地
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
DE69328771T2 (de) * 1992-02-24 2000-12-07 East Carolina University Green Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
EP0637915A4 (en) * 1992-05-01 1998-09-02 Univ Utah Res Found COMPOSITIONS AND METHODS FOR REGULATING THE PRODUCTION OF INTERLEUKIN-6 IN VIVO.
US5346997A (en) * 1992-08-26 1994-09-13 Murphy James G Agents for complexing sodium under biological conditions
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5439899A (en) * 1993-03-10 1995-08-08 Purdue Research Foundation Cosalane and related compounds having activity against aids and aids-related infections
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
AU701529B2 (en) * 1994-04-05 1999-01-28 Purdue Research Foundation NADH oxidase as a target in diagnosis and therapy
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US7893044B2 (en) * 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US6162450A (en) * 1995-05-15 2000-12-19 Avon Products, Inc. Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
US5922335A (en) * 1995-05-15 1999-07-13 Avon Products, Inc. Uses for ascorbyl-phosphoryl-cholesterol in topical compositions
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
DE69605556T2 (de) * 1996-05-14 2000-06-15 Avon Prod Inc Ascorbyl-phosphorylcholesterol
GB9612990D0 (en) * 1996-06-20 1996-08-21 Stanford Rock Ltd Compositions and methods for the treatment of chronic infections
US5885977A (en) * 1997-01-15 1999-03-23 Humanetics Corporation Use of Δ5 androstenes in the treatment of HIV wasting syndrome
US5902593A (en) * 1997-10-01 1999-05-11 Kent; Frances B. Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CN1328463A (zh) * 1998-11-24 2001-12-26 霍利斯-伊登医药公司 17－酮甾类化合物及其衍生物、代谢产物和前体在治疗丙型肝炎病毒和其他披膜病毒中的应用
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
AP1584A (en) * 1998-11-24 2006-03-01 Hollis Eden Pharmaceuticals Inc Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis.
AU1923500A (en) * 1998-11-27 2000-06-19 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
EP1422234A3 (en) * 1999-03-23 2010-12-08 Harbor BioSciences, Inc. Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
RU2417792C2 (ru) * 1999-03-23 2011-05-10 Харбор Биосайенсиз, Инк. Иммуномодуляторные стероиды
FR2792201B1 (fr) * 1999-04-15 2001-11-02 Donatien Mavoungou Procede du renforcement immunitaire et du developpement d'un transporteur lipidique pour une therapie genique anti-vih et anti-bacterienne
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
EP1553954A4 (en) * 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
SE439586B (sv) * 1975-09-05 1985-06-24 Kanebo Ltd Sett att framstella ett stabilt farmaceutiskt torrpreparat av ett alkalimetallsalt av dehydroepiandrosteronsulfat
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
ES8706717A1 (es) * 1983-08-02 1987-07-01 Research Corp Metodo de preparar esteroides
US4507289A (en) * 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US4602008A (en) * 1984-12-14 1986-07-22 Progenics, Inc. Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
NL8502571A (nl) * 1985-09-20 1987-04-16 Akzo Nv Steroiden met immunomodulerende eigenschappen.
JPS62201819A (ja) * 1985-11-13 1987-09-05 Res Dev Corp Of Japan 免疫不全症処置剤

Also Published As

Publication number Publication date
GB2204237B (en) 1991-02-06
BE1004315A5 (fr) 1992-11-03
DE3812595C2 (de) 1997-07-03
DK208188D0 (da) 1988-04-15
FR2615394A1 (fr) 1988-11-25
AT401470B (de) 1996-09-25
IL86089A (en) 1992-11-15
PH25907A (en) 1991-12-19
IT8847858A0 (it) 1988-04-15
FI881773A0 (fi) 1988-04-15
CA1325594C (en) 1993-12-28
DE3812595A1 (de) 1988-10-27
DK175582B1 (da) 2004-12-13
ATA98488A (de) 1996-02-15
KR880012233A (ko) 1988-11-26
NL194728B (nl) 2002-09-02
PT87259B (pt) 1992-08-31
AU1467888A (en) 1988-10-20
NL8800926A (nl) 1988-11-16
GR1002240B (en) 1996-04-22
DK208188A (da) 1988-10-17
SE8801406D0 (sv) 1988-04-15
NL194728C (nl) 2003-01-07
FI881773A (fi) 1988-10-17
PT87259A (pt) 1988-05-01
GB8808864D0 (en) 1988-05-18
IL86089A0 (en) 1988-09-30
JPS6425722A (en) 1989-01-27
GR880100248A (el) 1989-01-31
LU87202A1 (fr) 1988-11-17
US4956355A (en) 1990-09-11
FR2615394B1 (fr) 1994-09-23
JP2577771B2 (ja) 1997-02-05
NZ224272A (en) 1991-09-25
SE8801406L (sv) 1988-10-17
CH675358A5 (fi) 1990-09-28
GB2204237A (en) 1988-11-09
IT1227073B (it) 1991-03-14
OA08729A (en) 1989-03-31
AU608824B2 (en) 1991-04-18
KR960014988B1 (ko) 1996-10-23

Similar Documents

Publication Publication Date Title
SE503482C2 (sv) Användning av 17-ketosteroider, eventuellt åtföljande eller i kombination med ett immunomoduleringsmedel eller ett antiviralt medel, för framställning av ett läkemedel för användning vid profylax och terapi av en retroviral infektion
CA2223513C (en) Betulinic acid derivatives and uses therefor
US20210388320A1 (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
EP1068219B1 (en) Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
Cutts et al. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin
Huang et al. Effects of extracellular human immunodeficiency virus type 1 vpr protein in primary rat cortical cell cultures
CA1339854C (en) Viral treatment system
Roberts et al. N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients
US4704357A (en) Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
EP0415902B1 (en) Oxy- or thio-substituted fatty acid analogs for use in the treatment of retroviral infections
EP1675866A1 (en) Novel triterpene derivatives, preparation thereof and use thereof
Dore-Duffy Differential effect of prostaglandins and other products of arachidonic acid metabolism on measles virus replication in Vero cells
Satoh et al. Absence of natural killer (NK) cell activity against oligodendrocytes in multiple sclerosis
Blakeslee Jr et al. Human T-Cell Leukemia Virus I Induction by 5-lodo-2′-deoxyuridine and N-Methyl-N′-nitro-N-nitrosoguanidine: Inhibition by Retinoids, l-Ascorbic Acid, and dl-α-Tocopherol
Kristiansen et al. Effect of Selected Neuroleptic Agents and Stereo‐Isomeric Analogues on Virus and Eukaryotic Cells
Muhammad et al. Inhibition of Epstein-Barr virus by the triterpenoid betulin diphosphate and uvaol
NZ236303A (en) 17-ketosteroids, manufacture of aids medicament
WO2005072091A2 (en) Methods for inhibiting hiv and other viral infections by modulating ceramide metabolism
CN116421606A (zh) 小分子药物amg7703在抗流感病毒感染中的应用
AU735990B2 (en) Amino sugars and glycoproteins
IL90783A (en) Method for preventing the transmission of non-human living biological material to the VIH virus by using the antibiotic substance UB-8063

Legal Events

Date Code Title Description
NUG Patent has lapsed